Future Prospects of Global Laboratory Proficiency Testing Market

The treatment of gastroesophageal reflux disease (GERD) and stomach and intestinal ulcers has piqued the interest of healthcare professionals, owing to the growing prevalence of these conditions. GERD is a frequent health issue that can result in major medical consequences as well as a significant financial outlay for diagnosis and treatment. Heartburn and acid regurgitation are the two most commonly observed symptoms of GERD. To reduce the effects of stomach acids or to stop acid production, over-the-counter antacids, proton pump inhibitors, and H-2 receptor blockers are commonly utilised.
Ranitidine
is a histamine H2 antagonist that is used to treat gastroesophageal reflux
disease. It is available as an over-the-counter (OTC) and prescription medicine
(GERD). For up to 12 hours, ranitidine reduces stomach acid production. Erosive
esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome are all
treated with ranitidine. It can be administered either orally or intravenously.
Growing Research and Development
(R&D) on Ranitidine
Various
government and corporate research institutions are increasingly involved in
research and development studies to improve the efficacy of ranitidine and
analyse its potential to expand the scope of the ranitidine
market in the future.
Moreover, a
number of clinical trials are presently underway to determine and compare the
efficacy of ranitidine to other proton pump inhibitors like esomeprazole and
rabeprazole in reducing gastric acid in the stomach. The efficacy of ranitidine
is predicted to improve as a result of these research, and improved treatment
regimes for lowering excessive stomach acid production should be available in
the near future.
For example,
a Phase III clinical trial comparing the efficacy of rabeprazole extended
release (ER) 50 mg versus ranitidine 150 mg in the treatment of erosive
gastroesophageal reflux disease (eGERD) began in November 2015.
Comments
Post a Comment